HK1198921A1 - Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof - Google Patents

Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof Download PDF

Info

Publication number
HK1198921A1
HK1198921A1 HK14112445.0A HK14112445A HK1198921A1 HK 1198921 A1 HK1198921 A1 HK 1198921A1 HK 14112445 A HK14112445 A HK 14112445A HK 1198921 A1 HK1198921 A1 HK 1198921A1
Authority
HK
Hong Kong
Prior art keywords
ohepa
hetre
dgla
methods
antimicrobial compositions
Prior art date
Application number
HK14112445.0A
Other languages
English (en)
Chinese (zh)
Inventor
Jonathan Rowe
David Coughlan
Mehar Manku
Original Assignee
Dignity Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Limited filed Critical Dignity Sciences Limited
Publication of HK1198921A1 publication Critical patent/HK1198921A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14112445.0A 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof HK1198921A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261591036P 2012-01-26 2012-01-26
US61/591,036 2012-01-26
US13/478,990 2012-05-23
US13/478,990 US20120264705A1 (en) 2012-01-26 2012-05-23 Antimicrobial compositions comprising 15-hetre and methods of use thereof
PCT/US2013/023201 WO2013112876A1 (en) 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1198921A1 true HK1198921A1 (en) 2015-06-19

Family

ID=47006834

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112445.0A HK1198921A1 (en) 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Country Status (16)

Country Link
US (2) US20120264705A1 (https=)
EP (1) EP2806868A4 (https=)
JP (3) JP6557009B2 (https=)
KR (1) KR20140117379A (https=)
CN (1) CN104114166A (https=)
AU (1) AU2013211982A1 (https=)
BR (1) BR112014018421A8 (https=)
CA (1) CA2857046A1 (https=)
HK (1) HK1198921A1 (https=)
IL (1) IL232777A0 (https=)
MX (1) MX2014006947A (https=)
PH (1) PH12014501693A1 (https=)
RU (1) RU2014134720A (https=)
SG (1) SG11201404088TA (https=)
WO (1) WO2013112876A1 (https=)
ZA (1) ZA201403948B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
RU2014119948A (ru) * 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US9855236B2 (en) 2011-10-19 2018-01-02 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
GB201307082D0 (en) * 2013-04-19 2013-05-29 Dignity Sciences Ltd Pharmaceutical composition comprising 15-HETrE and methods of using the same
WO2015042442A1 (en) * 2013-09-19 2015-03-26 Dignity Sciences Limited Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) * 2014-01-10 2017-09-20 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
LT6177B (lt) 2014-10-10 2015-07-27 Uab "Biocentras" Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US20200206173A1 (en) 2017-08-30 2020-07-02 Conopco, Inc., D/B/A Unilever A personal care composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344930A (en) * 1975-10-30 1982-08-17 Colgate-Palmolive Company Skin care sponge
JP4926310B2 (ja) * 1996-02-15 2012-05-09 エルテーベー４・スウェーデン・アクチェボラーグ 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンｂ４またはその類似体の使用
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US6190645B1 (en) * 1999-07-15 2001-02-20 Playtex Products, Inc. Sunscreen for the scalp hair and hair
US20030073930A1 (en) * 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) * 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
CA2674210A1 (en) * 2005-12-30 2007-07-12 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
CA2670158A1 (en) * 2006-11-23 2008-05-29 Cargill, Incorporated Natural equivalent of chemically modified starch
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
EP2159732A1 (en) * 2008-08-21 2010-03-03 Thomson Licensing Method and device for code obfuscation
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8637298B2 (en) * 2009-06-16 2014-01-28 E I Du Pont De Nemours And Company Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof

Also Published As

Publication number Publication date
US20140171358A1 (en) 2014-06-19
JP2015504921A (ja) 2015-02-16
JP2018065818A (ja) 2018-04-26
JP2020023513A (ja) 2020-02-13
JP6557009B2 (ja) 2019-08-07
CN104114166A (zh) 2014-10-22
EP2806868A1 (en) 2014-12-03
BR112014018421A2 (https=) 2017-06-20
KR20140117379A (ko) 2014-10-07
RU2014134720A (ru) 2016-03-20
CA2857046A1 (en) 2013-08-01
BR112014018421A8 (pt) 2017-07-11
MX2014006947A (es) 2015-03-05
EP2806868A4 (en) 2015-08-26
PH12014501693A1 (en) 2014-10-20
SG11201404088TA (en) 2014-10-30
AU2013211982A1 (en) 2014-06-19
US20120264705A1 (en) 2012-10-18
IL232777A0 (en) 2014-07-31
WO2013112876A1 (en) 2013-08-01
ZA201403948B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
HK1198921A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
WO2015077503A8 (en) Autotaxin inhibitor compounds
EP4342537A3 (en) Semifluorinated alkane compositions
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
PH12019501469A1 (en) Compositions and methods for treating biofilms
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
PH12013501892A1 (en) Nutritional compositions including branched chain fatty acids for wound healing
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
EP3663366A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2015002932A8 (en) Antimicrobial compositions comprising hypochlorous acid and silver
HK1211867A1 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
HK1202448A1 (en) Topical formulation for administering a compound
IN2014DN07483A (https=)
EP4474011A3 (en) High elasticity hyaluronan compositions and methods of use thereof
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders